Related Experiment Video
Updated: May 17, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Russell Silver syndrome: a perspective on growth and the influence of growth hormone therapy
J V Mascarenhas1, Vageesh S Ayyar
1Department of Endocrinology, St. John's Medical College, Bangalore, India.
Insights
Russell Silver Syndrome (RSS) in a child with failure to thrive was diagnosed with growth hormone deficiency. Recombinant human growth hormone (rhGH) therapy significantly improved height, demonstrating its efficacy.
Area of Science:
- Pediatric Endocrinology
- Genetics and Rare Diseases
Background:
- Russell Silver Syndrome (RSS) is a rare genetic disorder characterized by intrauterine and postnatal growth retardation.
- Patients often present with failure to thrive, short stature, and distinct facial features.
Observation:
- A 6-year-old male with RSS presented with failure to thrive, short stature, relative macrocephaly, triangular facies, and clinodactyly.
- Hormonal analysis revealed low Insulin-like Growth Factor 1 (IGF-1) and basal Growth Hormone (GH) levels.
- A clonidine stimulation test confirmed complete GH deficiency.
Findings:
- The patient was initiated on recombinant human GH (rhGH) therapy at 8 years old due to financial constraints.
- After 19 months of rhGH treatment (1.5 IU/day), a height gain of 15 cm was achieved.
- Bone age assessment indicated a delay, with the bone age at 9 years being between 7-8 years.
Implications:
- This case highlights the effectiveness of rhGH therapy in improving linear growth in children with RSS and GH deficiency.
- Early diagnosis and timely intervention with GH therapy are crucial for optimizing outcomes in RSS patients.
- Addressing financial barriers is essential for consistent and effective treatment adherence in pediatric endocrine disorders.
Abstract:
A 6 years male child was referred to our Endocrinology clinic with complaints of failure to thrive and he displayed the characteristic features of Russell Silver Syndrome which included short stature, relative macrocephaly, triangular facies and bilateral clinodactyly. He had a birth weight of 2.14 kg and an expected target height of 170 cm. He was subjected to a hormonal analysis which revealed a normal thyroid profile, but low serum markers of growth namely IGF-1=68 ng/ml (52-297 ng/ml) and basal growth hormone (GH) (1.5 μg/l). No defects were detected on MRI of the sella. Therefore a growth hormone stimulation test with Clonidine was performed which confirmed complete GH deficiency (at 0 min=0.16 μg/l, 60 min=0.27 μg/l, 120 min=4.73 μg/l). He was commenced on rhGH therapy at 8 years of age (height=102 cm, SDS=-4.53), due to financial restraints. Following initiation of GH therapy (1.5 IU/day) for 19 months, a height gain of 15 cm was obtained (Height=117 cm, SDS=-3.05). Bone age at 9 yr. was between 7-8 years.
Related Concept Videos
Nature and Nurture
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Cushing Syndrome II: Pathophysiology
Growth versus Fixed Mindset
Cushing Syndrome I: Introduction
Mitogens and the Cell Cycle